IDO2 and cardiac arrest: Recently, our group has reported that pharmacologic pretreatment with an indoleamine 2,3-dioxygenase inhibitor before inducing cardiac arrest in rats improved post–cardiac arrest neurologic function while reducing systemic and cerebral kynurenine pathway activation.7 Altogether, this evidence suggests that the inhibition of the rate-limiting enzyme indoleamine 2,3-dioxygenase could represent a novel therapeutic target to reduce post–cardiac arrest brain injury and improve outcome.